PharmaTimes3d
Imfinzi receives NICE recommendation for lung cancer treatment
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
FiercePharma7d
AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell lung cancer
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
Imfinzi (durvalumab) for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...
Zacks.com on MSN7d
AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC ...
FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
pulmonologyadvisor2d
Imfinzi Approved for Limited-Stage Small Cell Lung Cancer
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
pharmaphorum7d
FDA clears AZ's Imfinzi for aggressive lung cancer
Imfinzi is already approved for extensive-stage SCLC based on the results of the CASPIAN trial, as well as for locally ...
Daily5d
AstraZeneca Imfinzi granted priority review by USFDA for muscle-invasive bladder cancer
Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...
Morningstar6d
IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI®(durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle ...
The Pharma Letter6d
Imfinzi recommended for rNSCLC
Imfinzi (durvalumab) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment ...
FDA accepts AstraZeneca's sBLA for Imfinzi for bladder cancer
AstraZeneca (AZN) said the FDA has accepted its supplemental Biologics License Application for Imfinzi for Priority Review for the treatment of muscle-invasive bladder cancer.